Epithelial Ovarian Cancer
▪ Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer and is the fifth leading cause of cancer-related deaths among women worldwide ▪ This cancer arises from epithelial cells of the ovary which are important for hormonal regulation ▪ This cancer arises from epithelial cells of the ovary, which are important for hormonal regulation and female reproduction ▪ Because of a lack of characteristic symptoms and early detection strategies, most ovarian cancer patients are diagnosed at stages III and IV, after the cancer has already metastasized to other organs cancer patients are diagnosed at stages III and IV, after the cancer has already metastasized to other organs ▪ The high mortality rate associated with this cancer is largely explained by the fact that the majority (~75%) of patients present at advanced stages with widely metastatic disease within the peritoneal cavity. These cancers grow rapidly, metastasize early, and have a very aggressive disease course Thus, ovarian cancer invasion and metastasis still represent a major hurdle that must be overcome to improve patient outcomes. 
Current status of EOC therapeutics

Unmet medical needs of anti-VEGF therapy in EOC ① Lack of therapeutic efficacy of Avastin
• According to clinical result for advanced ovarian cancer , bevacizumab extends progression-free survival up to ~4 months in combination with standard chemotherapy (carboplatin, paclitaxel)
• Based on clinical result for recurrent, platinum-resistant ovarian cancer, bevacizumab extends progressionfree survival up to ~3 months in combination with chemotherapy (carboplatin, gemcitabine)
② Side effects of Avastin
• Bevacizumab interrupts VEGF signaling on normal endothelial cells so that it cause various side effects including bleeding proteinuria hypertension gastrointestinal perforation stroke and heart attack including bleeding, proteinuria, hypertension, gastrointestinal perforation, stroke, and heart attack
③ Avastin resistance
• Long-term treatment of bevacizumab results in a drug resistance that is occurred by redundancy of tumorsecreted angiogenic factors, including placental growth factor, angiopoietin-2, bFGF, insulin-like growth factor, and epidermal growth factor factor, and epidermal growth factor
Tetraspanin 8 (TSPAN8) TSPAN8
A member of tetraspanin superfamily that forms tetraspain-enriched i d i (TEM ) l i ith i b t i microdomains (TEMs) complexing with various membrane proteins A tumor associated antigen highly overexpressed during the progression of colorectal, liver, pancreatic, and gastric cancers Its increased expression promotes liver and lung metastasis TSPAN8 may also act as an adaptor molecule, forming a l ith i b t i i l di CD151 complex with various membrane proteins, including CD151, EpCAM, claudin-7, E-cadherin, and CD44v6, that has been shown to promote cancer progression and metastasis H th l d l f TSPAN8 t t b i ti t d i EOC However, the relevance and role of TSPAN8 are yet to be investigated in EOC. 
